華海藥業(600521.SH):因公司供應的纈沙坦原料藥的雜質問題 山德士提起仲裁要求賠償1.15億美元
格隆匯5月13日丨華海藥業(600521.SH)公佈,近期,SANDOZ(山德士製藥有限公司,以下簡稱“山德士”,註冊地:瑞士)公司及其下屬六家公司因公司供應的纈沙坦原料藥的雜質問題,認為公司違反了與其簽訂的《框架供貨協議》項下的義務導致其遭受損失,向位於德國漢堡的中歐仲裁中心提起仲裁。根據《公司法》、《證券法》及《上市公司股票上市規則》等相關規定,現將有關仲裁事項公告如下:
仲裁申請人:山德士及其下屬六家公司
仲裁被申請人:浙江華海藥業股份有限公司
仲裁案件受理機構:Chinese European Arbitration Centre(中歐仲裁中心)
申請人仲裁請求:被申請人賠償申請人因雜質事件所遭受的所有直接和間接損失,包括已發生的,以及部分未來可能發生的損失(其中主要組成部分為因該產品的銷售損失所導致的利潤損失約6840萬美元)。申請人提出的未經第三方核實的賠償總額約1.15億美元。
2017年度,公司出售給山德士及其下屬公司的纈沙坦原料藥合計金額約為531萬美元;2018年1-6月份,公司出售給山德士及其下屬公司的纈沙坦原料藥合計金額約為673萬美元。
自纈沙坦事件發生以來,公司本着實事求是、公平合理的原則,積極與客户溝通解決補償相關事宜。截止目前,遵循原料藥供應業務的商業本質,根據與客户簽署的供貨合同等商業協議和有關法律法規,公司與除山德士外的其他大部分客户已達成共識,就其召回產品的相關直接成本進行適當補償,並簽署了相關協議或做了相應的安排。
目前,上述仲裁案件實體審理尚未開始,仲裁結果尚存在不確定性,公司亦無法準確判斷對本期利潤及期後利潤的影響。公司將聘請專業律師團隊代理應對該仲裁案件,在尊重客觀事實、分清雙方責任的基礎上,尋求公平合理的解決方案。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.